Journal article
Pharmacogenomic study of heart failure and candesartan response from the CHARM programme
Abstract
AIMS: The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programme consisted of three parallel, randomized, double-blind clinical trials comparing candesartan with placebo in patients with heart failure (HF) categorized according to left ventricular ejection fraction and tolerability to an angiotensin-converting enzyme inhibitor. We conducted a pharmacogenomic study of the CHARM trials with the objective …
Authors
Dubé M; Chazara O; Lemaçon A; Asselin G; Provost S; Barhdadi A; Perreault LL; Mongrain I; Wang Q; Carss K
Journal
ESC Heart Failure, Vol. 9, No. 5, pp. 2997–3008
Publisher
Wiley
Publication Date
October 2022
DOI
10.1002/ehf2.14026
ISSN
2055-5822